Track Abivax S.A. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Abivax S.A. ABVX · Stock Open Abivax S.A. in new tab

87.58 USD
EPS
-6.08
P/B
16.88
ROE
-252.35
Beta
-0.33
Target Price
163.58 USD
Loading chart...
Key Metrics
Earnings dateDec. 21, 2026
EPS-6.08
Book Value5.16
Price to Book16.88
Debt/Equity0.33
Growth
Revenue Growth-0.07%
Estimates
Forward P/E-22.68
Forward EPS-3.84
Target Mean Price163.58

DCF valuation

Model fair value for Abivax S.A. (ABVX)
Result
Sign in to run the valuation for ABVX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
12 analysts · consensus None · mean target 163.58 USD (low 142.00, high 181.00) · as of 10 Nov 2026
Low 142.00
Mean 163.58
High 181.00
Price 87.58
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Abivax S.A. Logo Abivax S.A. Analysis (ABVX)

France Healthcare Official Website Stock

Is Abivax S.A. a good investment? Abivax S.A. (ABVX) is currently trading at 87.58 USD. Market analysts have a consensus price target of 163.58 USD. This suggests a potential upside from current levels.

Earnings Schedule: Abivax S.A. is expected to release its next earnings report on Dec. 21, 2026. The market consensus estimate for Forward EPS is -3.84.

Investor FAQ

Does Abivax S.A. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Abivax S.A.?

Abivax S.A. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Dec. 21, 2026. The company currently has a trailing EPS of -6.08.

Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Exchange Ticker
PNK (United States) AAVXF
NASDAQ ABVX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion